跳到正文
原文
Endpoints News 生物医药· ENDPOINTS·· 2026-10-12AI 评分33

Mirum Pharmaceuticals的Livmarli在超罕见肝病晚期试验中显示疗效;First Tracks在乳糜泻领域取得进展

Mirum succeeds in rare liver disease trial; First Tracks delivers in celiac

AI 导读

Mirum Pharmaceuticals的Ileal bile acid transporter inhibitor Livmarli在超罕见肝病的晚期临床试验中显著降低了胆汁淤积性瘙痒。First Tracks在乳糜泻相关领域也取得了积极结果。

正文

Mirum Phar­ma­ceu­ti­cals’ late-stage win in ul­tra-rare liv­er dis­eases: The com­pa­ny’s ileal bile acid trans­porter in­hibitor Liv­mar­li sig­nif­i­cant­ly re­duced cholesta­t­ic pru­ri­tus ver­sus …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news